TNFRSF8 and diffuse large B-cell lymphoma: Thus, combining BV and ICIs might be an attractive or optimized second-line strategy for R/R DLBCL patients with both CD30 and EBV- positive, which has already been assessed in R/R NK/T-cell Lymphoma (NCT05316246).